Marc Castelltort

Trafalgar Capital Management (UK) LLP (Trafalgar UK) is an alternative investment manager headquartered in London, UK. The firm was founded by Christopher Aarons in 2001 and is wholly-owned by Trafalgar Capital Management Ltd. Trafalgar UK manages separate hedge-based strategies.

Trafalgar Capital Management (HK) Ltd. (Trafalgar HK) is a boutique investment management firm headquartered in Hong Kong. Formerly known as Megajoy Global Ltd., the firm was founded in 2010 and is owned by Trafalgar International Group SA in British Virgin Islands. Trafalgar HK manages two separate Hedge based strategies.

Life Biosciences, Inc. engages in the provision of research on aging and age-related diseases. It focuses on altered communication and inflammation, chromosomal instability, cellular senescence, loss of protoeostasis, metabolism, stem cell exhaustion, epigenetic alterations, and mitochondrial dysfunction. The company was founded by David Sinclair and Tristan Alexander Edwards in 2017 and is headquartered in Boston, MA.

Continuum Biosciences, Inc. operates as a biotech company that focuses on diseases such as obesity, diabetes, and ageing. The company was founded in 2017 and is headquartered in Blacksburg, VA.

Animal Biosciences, Inc. operates as a pre-commercialization and bio-pharmaceutical company. The firm develops therapeutics and supplements for pets, primarily dogs, cats and horses. The company was headquartered in Boston, MA.

JumpStart Fertility, Inc. operates in the health care industry. The company is headquartered in Chestnut Hill, MA.

Proto Axiom Pty Ltd. is an Australian company that focuses on investing in pre-clinical biotech companies to expand the growing bioscience industry. The company is based in Melbourne, Australia. The company has a disciplined and repeatable approach to investing by centralizing a world-class R & D team and licensing leading scientific IP to commercialize it. The company has an executive leadership with over 40 years of experience and a world-renowned scientific team with education from top academic institutions from across the globe, including Harvard. Despite Australia's strong biotech credentials, there is a distinct lack of early-stage venture capital funds to support and commercialize this science. The company was founded in 2021, and the CEO is Anthony Liveris.